Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XTL Biopharmaceuticals Ltd. (XTLB : NSDQ)

• Company Description    XTL Biopharmaceuticals Ltd. is a biopharmaceutical company developing drugs against hepatitis. Number of Employees: 0

• Price / Volume Information    Yesterday's Closing Price: $0.89 Daily Weekly Monthly 20 Day Moving Average: 92,989 shares Shares Outstanding: 8.81 (millions) Market Capitalization: $7.86 (millions) Beta: 1.18 52 Week High: $2.54 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.71% -8.34% 12 Week 15.69% 11.74% Year To Date 53.69% 53.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 26 BEN-GURION ST. - RAMAT GAN,L3 5112001 ISR ph: 972-3611-6600 fax: 972-3611-6605 info@xtlbio.com http://www.xtlbio.com

• General Corporate Information    Officers Noam Band - Chief Executive Officer Shlomo Shalev - Chairman Itay Weinstein - Chief Financial Officer Iris Shapira Yalon - Director Alexander Rabinovich - Director Peer Information XTL Biopharmaceuticals Ltd. (GSAC) XTL Biopharmaceuticals Ltd. (CASI) XTL Biopharmaceuticals Ltd. (ALCD.) XTL Biopharmaceuticals Ltd. (OMNN) XTL Biopharmaceuticals Ltd. (CGPI.) XTL Biopharmaceuticals Ltd. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98386D307 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 04/29/26 Share - Related Items Shares Outstanding: 8.81 Most Recent Split Date: 12.00 (4.00:1) Beta: 1.18 Market Capitalization: $7.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/29/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - - 06/30/25 - - Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 0.70 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - - Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - -0.01 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©